Abbott Laboratories (NYSE:ABT) traded at $113.16 at close of the session on Tuesday, March 19, made an upward move of 0.64% on its previous day’s price.
Looking at the stock we see that its previous close was $112.44 and the beta (5Y monthly) reads 0.74 . The company has a trailing 12-month PE ratio of 34.65. In terms of its 52-week price range, ABT has a high of $121.64 and a low of $89.67. The company’s stock has lost about -0.75% over that past 30 days.
Abbott Laboratories has a market cap of $196.35 billion and is expected to release its quarterly earnings report on Apr 17, 2024 – Apr 22, 2024. With its Forward Dividend at 2.08 and a yield of 1.84%, the company’s investors could be anxious for the ABT stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.96, with the EPS growth for the year raised at $4.61 for 2024 and $5.09 for next year. These figures represent 3.80% and 10.40% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $9.89 billion, with a low of $9.77 billion and a high of $10.17 billion. The median projection represents growth squeezing down to 11.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $42 billion, or 4.70% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the ABT stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Looking further, we note that the PEG ratio for the ABT stock currently stands at 4.44, and the current price level is -4.75% off its SMA20 and -1.89% from its 50-day simple moving average. The RSI (14) is pointing at 38.22 while the volatility over the past week is 2.26% and jumps to 1.70% over the past one month. The beta value is 0.74, while the average true range (ATR) is currently pointing at 2.27.
Coming back to Abbott Laboratories (NYSE:ABT), we note that the average 3-month trading volume was 5.24 million, while that of the preceding 10-day period stands at 6.52 million. Current shares outstanding are 1.73 billion.
The insiders hold 0.73% of the company’s shares while institutions hold 77.12%. The data shows that short shares as of Feb 29, 2024, stood at 14.92 million at a short ratio of 2.72. This represents a 0.86% short interest in shares outstanding on Feb 29, 2024. Shares short rose in February from the previous month at 12.7 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 2.81% up in year-to-date price movement.
